Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 226 participants.
Also called NCT02429258
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 226 participants
- Sponsor
- Registry
-
NCT02429258
-
- Other papers using this trial's data
- Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT02429258. Randomized; triple masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2015-10 (actual). Results posted on 2017-04-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin
- Condition
- Type II Diabetes
- Intervention (Drug)
- Farxiga
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Insulin
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct02429258- Content hash
6839c821526250c5c5ca08b3171108b5d71c6a489022af1b889e00d839b65840